Can-Fite BioPharma Ltd. (IL:CANF)
TASE:CANF
Top Page
Can Fite Bio
(TASE:CANF)
Select Model
Select Model
Rating:42Neutral
Price Target:
502.00
▼(-31.45% Downside)
Action:ReiteratedDate:03/28/26
The score is primarily constrained by weak financial performance (shrinking revenue, large losses, and ongoing cash burn) and bearish technical trends (trading below major moving averages with negative MACD). Valuation is also unfavorable due to deeply negative earnings and no dividend support, partially offset by a low-debt balance sheet.
Positive Factors
Intellectual Property
Expanded patent allowances across jurisdictions for namodenoson’s anti-obesity use deepen Can-Fite’s IP moat. Strong, broad patents support exclusivity for new indications, enabling longer-term commercial optionality and potential licensing or partnership revenue streams beyond oncology.
Negative Factors
Shrinking Revenue
Persistently very low and declining revenue means the company cannot self-fund development from operations. Continued top-line weakness increases dependence on external capital and raises execution risk if clinical programs need sustained funding before commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Intellectual Property
Expanded patent allowances across jurisdictions for namodenoson’s anti-obesity use deepen Can-Fite’s IP moat. Strong, broad patents support exclusivity for new indications, enabling longer-term commercial optionality and potential licensing or partnership revenue streams beyond oncology.
Read all positive factors
Can Fite Bio (CANF) vs. iShares MSCI Israel ETF (EIS)
Market Cap
₪21.79M
Dividend YieldN/A
Average Volume (3M)1.04M
Price to Earnings (P/E)―
Beta (1Y)-0.46
Revenue GrowthN/A
EPS GrowthN/A
CountryIL
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-19.82
Shares Outstanding4,285,093
10 Day Avg. Volume130,742
30 Day Avg. Volume1,039,800
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.77
Price to Sales (P/S)35.39
P/FCF Ratio-1.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.36
Revenue Forecast (FY)N/A
Can Fite Bio Business Overview & Revenue Model
Company Description
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, w...
How the Company Makes Money
null...
Can Fite Bio Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 560.00K | 438.40K | 674.00K | 743.00K | 810.00K | 853.00K |
| Gross Profit | 560.00K | 412.42K | 674.00K | 743.00K | 810.00K | 853.00K |
| EBITDA | -8.90M | -10.74M | -8.12M | -8.18M | -10.08M | -12.83M |
| Net Income | -8.80M | -10.64M | -7.88M | -7.63M | -10.17M | -12.60M |
Balance Sheet | ||||||
| Total Assets | 7.72M | 9.52M | 9.12M | 9.99M | 9.28M | 20.25M |
| Cash, Cash Equivalents and Short-Term Investments | 6.46M | 8.54M | 7.89M | 8.92M | 7.98M | 19.14M |
| Total Debt | 90.00K | 71.01K | 104.00K | 40.00K | 62.00K | 124.00K |
| Total Liabilities | 3.54M | 3.92M | 3.68M | 3.75M | 4.81M | 5.87M |
| Stockholders Equity | 4.18M | 5.59M | 5.44M | 6.24M | 4.47M | 14.38M |
Cash Flow | ||||||
| Free Cash Flow | -8.36M | -9.69M | -7.64M | -8.44M | -10.81M | -9.87M |
| Operating Cash Flow | -8.35M | -9.69M | -7.64M | -8.44M | -10.80M | -9.86M |
| Investing Cash Flow | -2.00K | -2.16K | 1.50M | 498.00K | 9.50M | -14.51M |
| Financing Cash Flow | 10.08M | 10.44M | 6.71M | 9.14M | 0.00 | 20.46M |
Can Fite Bio Technical Analysis
Negative
732.30
Price Trends
656.37
Negative
1526.39
Negative
2398.20
Negative
Market Momentum
-70.42
Negative
41.78
Neutral
29.62
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:CANF, the sentiment is Negative. The current price of 732.3 is above the 20-day moving average (MA) of 563.94, above the 50-day MA of 656.37, and below the 200-day MA of 2398.20, indicating a bearish trend. The MACD of -70.42 indicates Negative momentum. The RSI at 41.78 is Neutral, neither overbought nor oversold. The STOCH value of 29.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IL:CANF.
Can Fite Bio Risk Analysis
Can Fite Bio disclosed 68 risk factors in its most recent earnings report. Can Fite Bio reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
If a United States person is treated as owning at least 10% of our shares, such holder may be subject to adverse U.S. federal income tax consequences. Q4, 2023
Can Fite Bio Peers Comparison
UnderperformOutperform
Sector (51)
IL:CANF
Can Fite Bio
522.40
520.60
28922.22%
IL:XTLB
Xtl Bio
2.00
-2.30
-53.49%
IL:CBI
Clal Biotech
32.50
2.20
7.26%
IL:BLRX
Bioline Rx
1.30
-0.40
-23.53%
IL:BOLT
Biolight
270.00
-359.40
-57.10%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.